INSTITUT PASTEUR DE LILLE FONDATION

Their core work

Institut Pasteur de Lille is a biomedical research foundation in northern France focused on infectious diseases, immunity, and age-related pathologies. Their core work spans vaccine development (pertussis, tuberculosis), innate immunity research, and understanding links between neurodegenerative diseases like Alzheimer's and stroke. They contribute preclinical and early clinical trial capabilities to large European consortia, particularly in antimicrobial resistance and drug-resistant infections. As a Pasteur network institute, they bridge fundamental immunology research with translational medicine.

What they specialise in

How they've shifted over time

In their early H2020 period (2015–2017), IPL's work was broader — spanning neurodegenerative disease mechanisms (stroke/Alzheimer's), pertussis vaccinology, and metabolic immunology. Their more recent projects (2020 onward) show a sharp pivot toward antimicrobial resistance and infectious disease therapeutics, with ERA4TB and FAIR both targeting drug-resistant bacterial infections through different approaches (new TB regimens and immunomodulatory aerosol therapy). The throughline is immunology, but the application has narrowed from diverse disease areas toward combating resistant infections.

IPL is concentrating on drug-resistant infections and immunomodulatory treatments — expect them to seek partners in AMR clinical trials, aerosol drug delivery, and TB regimen development.

How they like to work

IPL never coordinates — they join as participant (4 projects) or third party (2 projects), consistently contributing specialized expertise to consortia led by others. With 109 unique partners across 19 countries, they operate in large European consortia (typical for health RIAs and IMI-style projects). This profile suggests a reliable specialist contributor that brings deep immunology capabilities without seeking project leadership overhead.

IPL has collaborated with 109 distinct partners across 19 countries, indicating a well-connected European network concentrated in health research. Their participation in large consortia like TBVAC2020 and ERA4TB connects them to major TB and infectious disease research hubs across Europe.

What sets them apart

As a Pasteur network foundation, IPL combines the academic rigor of a research institute with translational infrastructure for preclinical development and Phase I clinical trials. Their dual expertise in both adaptive immunity (vaccines, pertussis) and innate immunity (flagellin, Toll-like receptors) is unusual — most labs specialize in one. For consortium builders targeting AMR or TB, IPL offers immunology depth with proven capacity to handle large EU grants (EUR 3.3M on ERA4TB alone).

Highlights from their portfolio

• ERA4TB
  By far their largest EU grant (EUR 3.3M) — a major pan-TB regimen accelerator running until 2026, signaling deep commitment to tuberculosis drug development.
• FAIR
  Innovative approach using flagellin aerosol therapy to treat drug-resistant pneumonia — represents their emerging focus on immunomodulation against AMR.
• PERISCOPE
  Large-scale pertussis correlates-of-protection study combining systems vaccinology with biomarker discovery, demonstrating IPL's vaccine science capabilities.